omigapil

Omigapil (CGP3466B free base) is an orally active inhibitor of GAPDH nitrosylation that can prevent tau acetylation, memory deficits, and motor dysfunction induced by Aβ1-42 in mice, highlighting its potential for Alzheimer's disease research. It is an effective inhibitor of apoptosis and is applicable in studies of congenital muscular dystrophy (CMD). Additionally, Omigapil serves as a click chemistry reagent due to its Alkyne group, which can engage in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions with Azide-containing molecules.

CGP 3466B maleate (Omigapil maleate) is an orally bioavailable GAPDH nitrosylation inhibitor. Omigapil maleate abrogates Aβ1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice. Omigapil maleate has the potential for the research of Alzheimer's disease. Omigapil maleate (CGP3446B maleate) is a apoptosis inhibitor. Omigapil maleate can be used for the research of congenital muscular dystrophy (CMD).